IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more
IRLAB Therapeutics AB (publ) (IRLAB-A) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.097x
Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has a cash flow conversion efficiency ratio of 0.097x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr5.26 Million) by net assets (Skr54.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IRLAB Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how IRLAB Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
IRLAB Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asmallworld AG
SW:ASWN
|
-0.066x |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
-0.115x |
|
BLUELAKE MINERAL AB
F:5KG0
|
N/A |
|
Vertiqal Studios Corp.
PINK:VERTF
|
0.213x |
|
Almondz Global Securities Limited
NSE:ALMONDZ
|
-0.002x |
|
PT Puri Sentul Permai Tbk
JK:KDTN
|
0.045x |
|
Prashkovsky
TA:PRSK
|
-0.029x |
|
Orgenesis Inc
OTCQB:ORGS
|
0.193x |
Annual Cash Flow Conversion Efficiency for IRLAB Therapeutics AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of IRLAB Therapeutics AB (publ) from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr32.63 Million | Skr-65.59 Million | -2.010x | -41.14% |
| 2023-12-31 | Skr115.76 Million | Skr-164.85 Million | -1.424x | -190.40% |
| 2022-12-31 | Skr290.83 Million | Skr-142.61 Million | -0.490x | -252.28% |
| 2021-12-31 | Skr399.48 Million | Skr128.64 Million | 0.322x | +225.57% |
| 2020-12-31 | Skr347.88 Million | Skr-89.21 Million | -0.256x | +48.87% |
| 2019-12-31 | Skr181.83 Million | Skr-91.20 Million | -0.502x | -50.55% |
| 2018-12-31 | Skr212.48 Million | Skr-70.79 Million | -0.333x | +10.56% |
| 2017-12-31 | Skr155.00 Million | Skr-57.74 Million | -0.373x | +5.19% |
| 2016-12-31 | Skr103.89 Million | Skr-40.82 Million | -0.393x | -30.74% |
| 2015-12-31 | Skr92.03 Million | Skr-27.66 Million | -0.301x | -141.45% |
| 2014-12-31 | Skr88.57 Million | Skr-11.02 Million | -0.124x | -- |